These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17058138)

  • 41. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
    Karasawa K; Kaizu T; Niibe Y; Igaki H; Shinohara M; Tanaka Y; Matsuda T
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):208-12. PubMed ID: 12694840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant hormonal therapy: the Canadian experience.
    Labrie F; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M; Tetu B; Fradet Y; Bélanger A; Candas B
    Urology; 1997 Mar; 49(3A Suppl):56-64. PubMed ID: 9123738
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
    Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
    J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
    Michalski J; Winter K; Roach M; Markoe A; Sandler HM; Ryu J; Parliament M; Purdy JA; Valicenti RK; Cox JD
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e363-70. PubMed ID: 22633552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Results of external radiotherapy in localized cancer of the prostate].
    Domínguez Domínguez M; Camacho González JE; Ibáñez Suárez R; Palacios Martínez A; Román Rodríguez P; Salas Buzón C
    Actas Urol Esp; 2002 Jun; 26(6):392-7. PubMed ID: 12189733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis.
    Oh RJ; Yoshioka Y; Tanaka E; Shiomi H; Sumida I; Isohashi F; Suzuki O; Konishi K; Kawaguchi Y; Nakamura S; Kato M; Inoue T
    Radiat Med; 2006 Jan; 24(1):58-64. PubMed ID: 16715663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical and biological evaluation of the response to neoadjuvant hormone therapy before radiotherapy in nonmetastatic cancers of the prostate].
    Richaud P; Salem N; Gaston R; Mauriac L; Chacon B; Bussières E
    Cancer Radiother; 1998; 2(1):27-33. PubMed ID: 9749093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
    Perez CA; Michalski JM; Mansur D; Lockett MA
    Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
    Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
    Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AL; Dong L; Kamat A; Pisters L; Kuban DA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):14-9. PubMed ID: 15629589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer.
    Laverdière J; Nabid A; De Bedoya LD; Ebacher A; Fortin A; Wang CS; Harel F
    J Urol; 2004 Mar; 171(3):1137-40. PubMed ID: 14767287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
    Hallemeier CL; Zhang P; Pisansky TM; Hanks GE; McGowan DG; Roach M; Zeitzer KL; Firat SY; Husain SM; D'Souza DP; Souhami L; Parliament MB; Rosenthal SA; Lukka HR; Rotman M; Horwitz EM; Miles EF; Paulus R; Sandler HM
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1057-1065. PubMed ID: 30959123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.